TNF and HIV-1 Nef: An Intimate Interplay  by Herbein, Georges
EBioMedicine 13 (2016) 25–26
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryTNF and HIV-1 Nef: An Intimate InterplayGeorges Herbein
Department of Virology, Pathogens & Inﬂammation Laboratory, University of Franche-Comté, COMUE Bourgogne Franche-Comté University, UPRES EA4266, SFR FED 4234, CHRU Besançon,
Besançon, FranceChronic immune activation is a hallmark of HIV infection (Moir et al. pressing other viral constructs known as TNF inducers, such as Tat,
2011). Tumor necrosis factor (TNF) alpha is a proinﬂammatory cytokine
detected throughout the disease course in plasma and lymph nodes of
HIV-infected patients. The HIV-1 Nef protein is produced early during
the disease and is present in several biological forms: a virion-associat-
ed protein, a free soluble plasma protein, and in plasma extracellular
vesicles (pEV). A close interplay exists between Nef and TNF. Nef can
mimic TNF action at the cellular level by activating similar pathways, in-
cluding the NF-κB, AP1, JNK and AKT pathways (Herbein and Khan,
2008; Kumar et al., 2016). Therefore, both TNF and Nef proteins favor
immune activation, enhance HIV-1 transcription and replication, and
fuel the progression of the disease. Although antiretroviral therapy
(ART) efﬁciently suppresses HIV replication, immune activation and
low CD4+ T cell counts often persist parallel to the presence of TNF
and Nef in plasma.
The study by Ostalecki and colleagues in this issue of EBioMedicine
describes an alternative TNF secretionmechanismwhere Nef-mediated
routing of the TNF-converting enzyme ADAM17 into Rab4+ early
endosomes and the Rab27+ secretory pathway leads to intracellular
pro-TNF cleavage and secretion of vesicular TNF endosomes (Ostalecki
et al. 2016–in this issue). Additionally, Notch1 is required for the
endosomal trafﬁcking of ADAM17. Besides a plasma membrane (PM)-
associated TNF shedding, the study highlights that a larger pool of
pro-TNF is cleaved intracellularly and secreted through vesicular
endosomes. This alternative mechanism of TNF secretion was corrobo-
rated by careful analysis of lymph node sections from an aviremic pa-
tient under ART. Since both peripheral blood lymphocytes (PBLs) and
monocytes produce TNF, it is critical to show that both cell types secrete
TNF through vesicular TNF endosomes. This was indeed clearly demon-
strated by incubation of both cell types with HIV-pEV, showing a typical
secretion phenotype. In addition, endosomal TNF secretion from CD4+/
CD45+ T cells was observed in a lymph node obtained from a non-vire-
mic HIV-infected individual. The speciﬁc role of Nef in the secretion of
vesicular TNF endosomes was further demonstrated since only vesicles
generated from Nef-transfected HEK293T cells, but not from cells ex-E-mail address: georges.herbein@univ-fcomte.fr.
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The presence of viral components has been reported in exosomes re-
leased from cells infectedwith Epstein-Barr virus, cytomegalovirus, her-
pes simplex virus and hepatitis C virus (Schorey and Harding, 2016). In
HIV infection, Nef-expressing exosomes from infected cells favor viral
replication (Arenaccio et al., 2014). The respective role of classical PM-
associated TNF shedding and alternative endosomal TNF secretion in
HIV pathogenesis has to be clariﬁed in future studies. Although the au-
thors report a preferential use of the alternative TNF pathway in the tis-
sue sample studied,we cannot exclude the preferential activation of one
pathway over the other depending on the stage of the HIV disease and/
or the tissue studied.
Both Nef and TNF activate NF-κB which enhances HIV-1 transcrip-
tion and replication. So far, most studies have used soluble recombinant
Nef and TNF proteins to assess their effects on the viral cycle. It would be
of interest to decipher the effect of HIV-pEV on viral transcription and
replication in several cell types including primary PBLs and mono-
cytes/macrophages. In addition, Nef and TNF have been reported to
favor the survival of productively infected CD4+ T lymphocytes, which
requires endogenous Nef expression as well as activation by PM-associ-
ated TNF expressed on the surface of macrophages (Mahlknecht et al.,
2000). The role of PM-associated TNF and vesicular TNF inNef-mediated
blockade of CD4+ T cell apoptosis has to be assessed in future studies. In
fact, CD4+ T cell apoptosis has been reported to be increased following
exposure to Nef-containing exosomes released from transfected T cell
lines and could explain depletion of uninfected CD4+ T cells in HIV-in-
fected patients (Lenassi et al., 2010). These apparently contradictory re-
sults could also depend on the type of cell releasing the vesicles, the
target cells, and the viral and cellular components of the exosomes.
Since the resistance to apoptosis of infected CD4+ T cells might partici-
pate in the formation and maintenance of viral reservoirs in HIV-infect-
ed people, the role of PM-associated TNF and vesicular TNF has to be
studied in regard to HIV-1 latency. The persistent immune activation
observed in non-viremic patients under ART especially in the presence
of TNF and Nef could favor the formation of a viral reservoir (Siliciano
and Siliciano, 2016). HIV integration and the establishment of latency
in CCL19-treated resting CD4+ T cells have been shown to require acti-
vation of NF-κB (Saleh et al., 2016). Since both TNF and Nef activate NF-
κB, the chronic immune activation observed in non-viremic patientsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
26 G. Herbein / EBioMedicine 13 (2016) 25–26under ART could impair the clearance of the viral reservoirs. New ther-
apeutic approaches will need to control virus replication through ART
but also to curtail immune activation with new therapeutic tools, possi-
bly including anti-TNF agents.
Disclosures
The author declares no conﬂicts of interest.
Acknowledgements
Research performed in our laboratories is supported by the Univer-
sity of Franche-Comté, the Agence Nationale de Recherches sur le Sida
et les Hepatites Virales (ANRS, n°13543 and 13544) and HIVERA 2013
(EURECA project).
References
Arenaccio, C., Chiozzini, C., Columba-Cabezas, S., Manfredi, F., Affabris, E., Baur, A., et al.,
2014. Exosomes from human immunodeﬁciency virus type 1 (HIV-1)-infected cellslicense quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and
ADAM17-dependent mechanism. J. Virol. 88, 11529–11539.
Herbein, G., Khan, K.A., 2008. Is HIV infection a TNF receptor signalling-driven disease?
Trends Immunol. 29, 61–67.
Kumar, A., Abbas,W., Colin, L., Khan, K.A., Bouchat, S., Varin, A., et al., 2016. Tuning of AKT-
pathway by Nef and its blockade by protease inhibitors results in limited recovery in
latently HIV infected T-cell line. Sci. Rep. 6, 24090.
Lenassi, M., Cagney, G., Liao, M., Vaupotic, T., Bartholomeeusen, K., Cheng, Y., et al., 2010.
HIV Nef is secreted in exosomes and triggers apoptosis in bystander CD4+ T cells.
Trafﬁc 11, 110–122.
Mahlknecht, U., Deng, C., Lu, M.C., Greenough, T.C., Sullivan, J.L., O'Brien, W.A., et al., 2000.
Resistance to apoptosis in HIV-infected CD4+ T lymphocytes is mediated by macro-
phages: role for Nef and immune activation in viral persistence. J. Immunol. 165,
6437–6446.
Moir, S., Chun, T.W., Fauci, A.S., 2011. Pathogenic mechanisms of HIV disease. Annu. Rev.
Pathol. 6, 223–248.
Ostalecki, C., Wittki, S., Lee, J.-H., Geist, M.M., Tibroni, N., Harrer, T., et al., 2016. HIV Nef-
and Notch1-dependent endocytosis of ADAM17 induces vesicular TNF secretion in
chronic HIV infection. EBioMedicine 13, 294–304 (in this issue).
Saleh, S., Lu, H.K., Evans, V., Harisson, D., Zhou, J., Jaworowski, A., et al., 2016. HIV integra-
tion and the establishment of latency in CCL19-treated resting CD4+ T cells require
activation of NF-κB. Retrovirology 13, 49.
Schorey, J.S., Harding, C.V., 2016. Extracellular vesicles and infectious diseases: new com-
plexity to an old story. J. Clin. Invest. 126, 1181–1189.
Siliciano, J.D., Siliciano, R.F., 2016. Recent developments in the effort to cure HIV infection:
going beyond N = 1. J. Clin. Invest. 126, 409–414.
